Skip to content
Catalyst
Late-onset sepsis incidence (neonatal)

1 finding · 1 compound · by evidence strength. No dose is advised.

Fig. 2 Late-onset sepsis incidence (neonatal)1 compound outer ring on requestSelected Late-onset sepsis incidence (neonatal) · centre
×1.60
Labels
Measured outcomeInspector

Late-onset sepsis incidence (neonatal)

Findings drawn, by strength

1finding · 1 compound

  • Very limited1
Keys

← → round a ring↑ ↓ out and inEnter selecte the outer ringf fit to view+ − zoomEsc clearclick a node to select it

Compound lowersFindingsStrongest
1
Very limited

Not pooled · no summary effect · point at a mark · Tab, then the arrow keys

Reported to move it1 finding

  1. lactoferrinMoved: lowersEffect, as reportedRR0.34[0.17 to 0.7]Evidence: Very limitedPaper: PMID 198090232009
    Who
    Very low birth weight (<1500 g) neonates in 11 Italian tertiary neonatal intensive care units
    Dose studied
    100 mg/day orally from birth until day 30 of life (day 45 for neonates <1000 g at birth)

    Incidence of late-onset sepsis was significantly lower in the BLF and BLF plus LGG groups (9/153 [5.9%] and 7/151 [4.6%], respectively) than in the control group receiving placebo (29/168 [17.3%]) (risk ratio, 0.34; 95% confidence interval, 0.17-0.70; P = .002 for BLF vs control and risk ratio, 0.27; 95% confidence interval, 0.12-0.60; P < .001 for BLF plus LGG vs control).”

    Quoted verbatim from Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial.RCTPermalink

How it is measured

Proportion of neonates who develop late-onset sepsis, sepsis arising after the first 72 hours of life (48 hours where the source draws the line there), over a stated period. The case definition is recorded with each finding: culture-proven sepsis, clinical sepsis, or the two together as confirmed or suspected sepsis; a culture-proven count is compared only with a culture-proven count.

Partial overlaps, not equivalences

  • HP:0040187

Papers about it

As an endpoint3

Show the papersHide the papers
  • Effect of bovine lactoferrin on prevention of late-onset sepsis in infants <1500 g: a pooled analysis of individual patient data from two randomized controlled trials.

    Biochemistry and cell biology2021PMID 32931708Via: named in the paper, as read

  • Randomized controlled trial of lactoferrin for prevention of sepsis in peruvian neonates less than 2500 g.

    The Pediatric infectious disease journal2015PMID 25973934Via: named in the paper, as read

  • Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial.

    JAMA2009PMID 19809023Via: named in the paper, as read

Newest

  • Effect of bovine lactoferrin on prevention of late-onset sepsis in infants <1500 g: a pooled analysis of individual patient data from two randomized controlled trials.

    Biochemistry and cell biology2021PMID 32931708As an endpoint

  • Randomized controlled trial of lactoferrin for prevention of sepsis in peruvian neonates less than 2500 g.

    The Pediatric infectious disease journal2015PMID 25973934As an endpoint

  • Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial.

    JAMA2009PMID 19809023As an endpoint